(c) 2024 PillSync.com

ezetimibe 10 MG Simvastatin 10 MG Oral Tablet

1 INDICATIONS AND USAGE Ezetimibe and simvastatin tablets Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. Ezetimibe and simvastatin tablets are a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin) indicated: ( 1 ) As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.

actavis pharma, inc.


4 years ago ROUND BROWN Logo 511 ezetimibe 10 MG  Simvastatin 10 MG Oral Tablet

ROUND BROWN Logo 511

4 years ago ROUND BROWN Logo 511 ezetimibe 10 MG  Simvastatin 10 MG Oral Tablet

Logo 511 ROUND BROWN

16 HOW SUPPLIED/STORAGE AND HANDLING

EZETIMIBE AND SIMVASTATIN tablets are supplied as follows: Strength How Supplied NDC Tablet Description 10 mg/10 mg unit of use bottles of 30 45963-565-30 Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 511 on one side and on opposite side. unit of use bottles of 90 45963-565-08 10 mg/20 mg unit of use bottles of 30 45963-566-30 Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 512 on one side and on opposite side. unit of use bottles of 90 45963-566-08 10 mg/40 mg unit of use bottles of 30 45963-567-30 Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 513 on one side and on opposite side. unit of use bottles of 90 45963-567-08 10 mg/80 mg unit of use bottles of 30 45963-568-30 Light tan, slightly speckled, capsule shaped, unscored, biconvex tablet debossed with 515 on one side and on opposite side. unit of use bottles of 90 45963-568-08 Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Keep container tightly closed. Dispense in a tight, light-resistant container as defined in the USP. 1 1 1 1


More pills like ROUND Logo 511












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site